Urology News and Research

Latest Urology News and Research

Taiho, Servier sign exclusive license agreement to develop and commercialize TAS-102 drug

Taiho Pharmaceutical Co., Ltd.(Japan) and Servier (France) announced on June 15 that they have entered into an exclusive license agreement on June 12, 2015 for the development and commercialization of TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride) in Europe and other countries.

15 Jun 2015

Men who use finasteride to treat benign prostate enlargement experience worsening ED

Men with benign prostate enlargement who used finasteride (also known as proscar and propecia) to treat their condition, experienced worsening erectile dysfunction (ED) that did not resolve with continued treatment. In addition, they experienced a reduction in their testosterone levels leading to hypogonadism (little to no production of sex hormones).

14 Jun 2015

Findings underscore the value of emotional, informational support for prostate cancer patients

A study led by the University at Buffalo and Roswell Park Cancer Institute has identified beliefs and personality traits that are associated with higher levels of distress in newly diagnosed prostate cancer patients.

10 Jun 2015

Only 50% of men can remember their last medical check-up, shows new national survey

A new national survey about men and their cars, commissioned by Orlando Health, found that more than 80 percent of men could remember the make and model of their first car, but only about half could remember the last time they went to the doctor for a check-up.

10 Jun 2015

Kravis Children's Hospital named one of country's top children's hospitals in pediatric specialties

The Kravis Children's Hospital at Mount Sinai ranked again among the country's top children's hospitals in pediatric specialties, according to the newly issued U.S. News & World Report's "Best Children's Hospitals" guidebook for 2015-2016.

9 Jun 2015

Janssen begins rolling submission of daratumumab BLA to FDA for treatment of patients with multiple myeloma

Janssen Research & Development, LLC has initiated the rolling submission of its Biologic License Application (BLA) for daratumumab to the U.S. Food and Drug Administration (FDA) for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), or who are double refractory to a PI and an IMiD.

7 Jun 2015

Actavis receives FDA approval to market NATRELLE INSPIRA round gel-filled textured breast implants

Actavis plc, which recently completed the acquisition of Allergan, Inc., today announced that the company has received approval from the U.S. Food and Drug Administration to market NATRELLE INSPIRA round gel-filled textured breast implants, offering women undergoing reconstruction, augmentation or revision surgery another breast shaping option for a customized result.

5 Jun 2015

Updated SOGC guidelines include FIBRISTAL as only approved medical treatment for uterine fibroids

The Society for Obstetrics and Gynecology of Canada has issued updated guidelines for the management of uterine fibroids (uterine leiomyomas), which now include the first and only approved medical treatment for uterine fibroids: FIBRISTAL (ulipristal acetate).

4 Jun 2015

Study explores 'laser welding' for sealing corneal transplants

Some 30,000 years ago, prehistoric man wielded animal bones as needles to suture otherwise lethal wounds. This tactic has been used, and improved upon, over time and remains the basis of surgical procedures conducted today. Even with radical new surgical techniques, which rely on metallic and polymeric staples or chemical adhesives to seal incisions, infection and permanent scarring remain major concerns. The success of any wound closure is entirely dependent on the physician's skill set alone.

4 Jun 2015

Ultrasound becoming the most widely used imaging tool in medicine today

Mention "ultrasound" and most people likely will think of an image of a fetus in a mother's womb. But while providing peeks at the not-yet-born is one of ultrasound's most common applications, that's only a small part of the picture.

3 Jun 2015

FDA approves Actavis ANDA for guaifenesin/pseudoephedrine tablets to relieve chest congestion

Actavis plc and its partner Perrigo Company plc announced today that Actavis has received U.S. Food and Drug Administration approval for its Abbreviated New Drug Application for guaifenesin/pseudoephedrine tablets and that Perrigo will begin shipments in time for the cough/cold season to its retail and wholesale customers in the U.S. The product will be packaged and marketed under store and proprietary brands and will be a high quality, value alternative to Mucinex® D tablets.

2 Jun 2015

CHLA opens doors of new Encino outpatient care center

Children's Hospital Los Angeles opened the doors of its new outpatient care center in Encino today. The pediatric medical facility, Children's Hospital Los Angeles - Encino, will be staffed by physicians who are Board-certified in pediatric specialties and subspecialties, including hematology-oncology, nephrology, neurology, orthopaedics, pediatric surgery and urology.

2 Jun 2015

Zinc levels linked to formation of kidney stone

New research on kidney stone formation reveals that zinc levels may contribute to kidney stone formation, a common urinary condition that can cause excruciating pain. The research found that zinc may be the core by which stone formation starts.

2 Jun 2015

Actavis acquires Auden Mckenzie

Actavis plc today announced that it has completed its acquisition of Auden Mckenzie Holdings Limited, a dynamic and fast growing company focused on the development, licensing and marketing of niche generic medicines and proprietary brands in the UK.

1 Jun 2015

Tennessee physician offers innovative painless procedure for postmenopausal patients

Dr. Yair Walzer has added a leading edge treatment to his practice to resolve vaginal health issues often caused by menopause. The MonaLisa Touch™, an in-office procedure that is virtually painless and requires no anesthesia, received FDA clearance in 2014.

30 May 2015

SNPs predict sunitinib outcome in mRCC

Research has confirmed that single nucleotide polymorphisms in genes related to the processing of sunitinib influence the outcome of treatment for metastatic renal cell carcinoma.

29 May 2015

RegenScientific gets FDA approval for Renu Gel injectable implant

RegenScientific announced that it has received FDA-clearance for its Renu Gel injectable implant indicated for vocal fold injection augmentation and today the company commenced shipments of this new product to physicians and hospitals in the United States.

28 May 2015

Actavis announces FDA approval of VIBERZI (eluxadoline) for IBS-D treatment

Actavis plc announced today that VIBERZI (eluxadoline) was approved by the Food and Drug Administration as a twice-daily, oral treatment for adults suffering from irritable bowel syndrome with diarrhea (IBS-D). VIBERZI (eluxadoline) has mixed opioid receptor activity, it is a mu receptor agonist, a delta receptor antagonist, and a kappa receptor agonist.

28 May 2015

Actavis creates collaborative program to improve care for patients with multidrug-resistant infections

Actavis plc, a leading global specialty pharmaceutical company committed to infectious disease treatment innovation, today announced the creation of SHARE ID (Sharing Hospital data to Advance Research and Enhance patient care in Infectious Diseases), a collaborative program to leverage real-world data to advance the delivery and effectiveness of care for patients with serious infections due to antibiotic-resistant pathogens.

27 May 2015

RCC benefit independent of sorafenib, sunitinib sequence order

Sequential treatment with sorafenib followed by sunitinib is not superior to sunitinib followed by sorafenib in patients with advanced or metastatic renal cell carcinoma, suggests research published in European Urology.

21 May 2015

Urology News and Research

Latest Urology News and Research

Taiho, Servier sign exclusive license agreement to develop and commercialize TAS-102 drug

Men who use finasteride to treat benign prostate enlargement experience worsening ED

Findings underscore the value of emotional, informational support for prostate cancer patients

Only 50% of men can remember their last medical check-up, shows new national survey

Kravis Children's Hospital named one of country's top children's hospitals in pediatric specialties

Janssen begins rolling submission of daratumumab BLA to FDA for treatment of patients with multiple myeloma

Actavis receives FDA approval to market NATRELLE INSPIRA round gel-filled textured breast implants

Updated SOGC guidelines include FIBRISTAL as only approved medical treatment for uterine fibroids

Study explores 'laser welding' for sealing corneal transplants

Ultrasound becoming the most widely used imaging tool in medicine today

FDA approves Actavis ANDA for guaifenesin/pseudoephedrine tablets to relieve chest congestion

CHLA opens doors of new Encino outpatient care center

Zinc levels linked to formation of kidney stone

Actavis acquires Auden Mckenzie

Tennessee physician offers innovative painless procedure for postmenopausal patients

SNPs predict sunitinib outcome in mRCC

RegenScientific gets FDA approval for Renu Gel injectable implant

Actavis announces FDA approval of VIBERZI (eluxadoline) for IBS-D treatment

Actavis creates collaborative program to improve care for patients with multidrug-resistant infections

RCC benefit independent of sorafenib, sunitinib sequence order

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Urology News and Research

Latest Urology News and Research

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in